Child care apopka fl: For Our Parents – ACA

Clinical and pharmacological group: Antibacterial, anti-inflammatory and vasoconstrictive drug for local use in ENT practice

Pharmacotherapeutic group: Glucocorticosteroid for topical use + antibiotics (aminoglycoside + cyclic polypeptide) + alpha-adrenomimetic

Pharmacological action

Combination preparation for topical use in otorhinolaryngology. Dexamethasone has an anti-inflammatory effect on the nasal mucosa, neomycin and polymyxin B have an antibacterial effect.

Dexamethasone is well absorbed when applied topically, its absorption increases with inflammation of the mucous membrane. With the combination of these antibiotics, the spectrum of antibacterial action on most gram-positive and gram-negative microorganisms that cause infectious and inflammatory diseases of the nasal cavity and paranasal sinuses expands.

Indications for Polydex with phenylephrine

Inflammatory and infectious diseases of the nasal cavity, pharynx, paranasal sinuses:

• acute and chronic rhinitis,
• acute and chronic nasopharyngitis,
• sinusitis.

Open list of ICD-10 codes

Dosing regimen

Adults: 1 injection in each nostril 3-5 times a day.

Children aged 2.5 to 18 years: 1 spray in each nostril 3 times a day.

Duration of treatment 5-10 days.

Side effects

Local allergic reactions are possible.

In the event of unusual reactions, you should consult your doctor about the advisability of further use of the drug.

Contraindications for use

• Suspicion on the Closing Uglucu,
• Simultaneous MAO inhibitors,
• Viral Diseases,
• , accompanied by albuminuria,
• .0186
  
• pregnancy,
• breastfeeding period,
• children under 2.5 years of age,
• hypersensitivity to the components of the drug.

Use the drug with caution in patients with arterial hypertension, coronary artery disease, hyperthyroidism.

Use in pregnancy and lactation

Contraindicated in pregnancy and lactation.

Application for violations of kidney function

The use of the drug is contraindicated in kidney diseases accompanied by albuminuria, renal failure.

Use in children

Contraindicated in children under 2.5 years of age.

Special instructions

When using, the vial should be held in an upright position with the atomizer facing up.

Do not use to wash the paranasal sinuses.

Avoid contact with eyes. In case of accidental contact with the eyes and other mucous membranes, rinse immediately with plenty of water.

Attention athletes: this product contains components that can give a positive result in doping control.

Influence on the ability to drive vehicles and mechanisms

There is no evidence of a negative effect of the drug on the ability to drive a car and other vehicles.

Overdose

Due to the low degree of absorption into the systemic circulation, overdose is unlikely.

Drug interactions

Drug interactions due to phenylephrine content.

Phenylephrine reduces the hypotensive effect of diuretics and antihypertensive drugs (including methyldopa, mecamylamine, guanadrel, guanethidine). If such a combination cannot be avoided, then medical supervision is necessary.

No clinically significant drug interactions with other medicinal products have been identified.

Storage conditions of Polydex with phenylephrine

The drug should be stored out of the reach of children at a temperature not exceeding 25°C.

Shelf life of Polydex with phenylephrine

Shelf life – 3 years. Do not use after the expiry date stated on the package.

Sales conditions

The drug is available by prescription. pharmacy
LASOLVAN® RHINO

Representative office:
BOEHRINGER INGELHEIM INTERNATIONAL GmbH ATX code: R01AA09 Marketing authorization holder:
BOEHRINGER INGELHEIM INTERNATIONAL, GmbH
manufactured by ISTITUTO de ANGELI, S.r. ANGELI.
tramazoline

Presentation, composition and packaging
Pale yellow, transparent nasal spray with eucalyptus scent.
1 ml
Tramazoline hydrochloride monohydrate 1.265 mg,
which corresponds to the content of tramazolin hydrochloride 1.18 mg – 30.36 mg, glycerol 85% – 10.12 mg, magnesium sulfate heptahydrate – 714 mcg, magnesium chloride hexahydrate – 510 mcg, calcium chloride dihydrate – 164 mcg, sodium bicarbonate – 20 mcg, sodium chloride – 2. 651 mg, cineol (eucalyptol) – 101 mcg, levomenthol (L-menthol) – 202 mcg, racemic camphor – 202 mcg, purified water – up to 1 ml.

10 ml – dark glass bottles (1) with dosing device and nasal adapter – carton packs.

Clinico-pharmacological group: Vasoconstrictor drug for local use in ENT practice
Registration nos.:
• nasal spray 0.118%: fl. 10 ml – P N015956/01, 08/24/11. The validity period of the reg. beats is not limited.
———————————————— ——————————-
The description of the medicinal product LASOLVAN® RINO is based on the officially approved instructions for use of the drug LASOLVAN® RINO for specialists and approved by the manufacturer for the 2013 edition.
———————————————— ——————————-
Pharmacological action | Pharmacokinetics | Indications | Dosing regimen | Side effect | Contraindications | Pregnancy and lactation | Special Instructions | Overdose | Drug interaction | Terms of dispensing from pharmacies | Storage conditions and expiration dates
————————————– ————————————
Pharmacological action
The active substance of the drug Lazolvan® Rino – tramazolin hydrochloride, alpha2-adrenergic agonist, causes vasoconstriction. When applied to the mucous membranes of the nose, due to the vasoconstrictor effect, the drug reduces swelling. As a result, the patency of the nasal passages is quickly restored, nasal breathing is facilitated for a long time.

The action of the drug begins within the first 5 minutes and lasts 8-10 hours.
Pharmacokinetics
No pharmacokinetic studies have been conducted in humans. The pharmacokinetics of tramazolin has been studied in rats, rabbits and monkeys. It is shown that after the use of the drug inside or intranasally absorbed 50-80% of the administered dose. Tramazoline and its metabolites are distributed in all internal organs, Cmax is noted in the liver.

After oral or topical administration, the main metabolites are determined in the urine. Terminal T1/2 is from 5 to 7 hours. otitis media (eustachitis) to facilitate the outflow of the contents of the paranasal sinuses (on the recommendation of a doctor).

Dosing mode
Adults and children over 6 years of age are prescribed one injection in each nasal passage (up to 4 injections in each nasal passage per day).
Do not use the drug for more than 5-7 days without a doctor’s prescription.
Instructions for use of

dosing vial

Clear nasal passages before injection.
1. Remove the protective cap.
2. Before first use, several sprays into the air must be made until a stable cloud of aerosol appears. After that, the dosing device is ready for use.
3. Insert the tip into the nasal passage and make one injection.
Repeat the procedure for the other nasal passage. After removing the tip, take a normal breath through the nose.
4. Put on the protective cap.

It is recommended to clean the handpiece after each use.

Side effects
From the nervous system: rarely (≥0.01% and from the cardiovascular system: infrequently (≥0.1% and from the respiratory system: often (≥1% and from the digestive system: infrequently (≥0.1% and From the side of the immune system: the frequency is not established * – hypersensitivity.0002 From the side of the skin and subcutaneous tissues**: frequency not established* – rash, itching, swelling of the skin.
Other: frequency not established * – swelling of the mucous membrane **, fatigue.
* Adverse events, the connection of which with the drug was regarded as possible, registered with the widespread use of the drug. The frequency of these rare events is difficult to estimate.
** As symptoms of hypersensitivity.

Contraindications to the use of the drug LASOLVAN® RINO
– angle-closure glaucoma,
– atrophic rhinitis,
– operations on the skull performed through the nasal cavity (in history),
– children under 6 years of age,
– hypersensitivity to tramazolin hydrochloride or benzalkonium hydrochloride, as well as to other components of the drug.

Precautions
In patients with arterial hypertension, heart disease, hyperthyroidism, prostatic hyperplasia, pheochromocytoma, porphyria, the drug should be used only on the advice of a physician due to the potential risk of systemic absorption of the drug.
Caution should be exercised when taking MAO inhibitors, tricyclic antidepressants, vasopressor drugs and antihypertensive drugs.
Use of the drug LASOLVAN® RHINO during pregnancy and lactation

Long-term experience of use shows that Lasolvan® RHINO does not adversely affect pregnancy. The safety of the drug during lactation has not been confirmed. Lazolvan® Rhino should not be used in the first trimester of pregnancy. At later stages of pregnancy and during breastfeeding, the use of the drug is allowed only after consulting a doctor.

Special instructions
If after 7 days of taking the drug there are no positive dynamics of symptoms, it is necessary to decide whether to stop taking the drug or continue treatment. Long-term use of nasal vasoconstrictor drugs can lead to the development of chronic inflammation and nasal congestion, as well as to atrophy of the nasal mucosa.
Avoid contact with eyes.

Influence on the ability to drive vehicles and control mechanisms
Studies on the effect of the drug on the ability to drive a car and machinery have not been conducted. However, when taking the drug, such undesirable effects as hallucination, drowsiness, sedation, dizziness and fatigue are possible. Therefore, care must be taken when driving and operating machinery.
If the above side effects occur, potentially hazardous tasks such as driving and operating machinery should be avoided.

Overdose
Symptoms: following an increase in blood pressure and tachycardia, a drop in blood pressure, the development of shock, reflex bradycardia, and a decrease in body temperature are possible (especially in children).
By analogy with other alpha-sympathomimetics, the clinical picture of intoxication may be indistinct, since the phases of stimulation and depression of the central nervous system and the cardiovascular system can replace each other.
Especially in children, intoxication leads to effects on the central nervous system with the development of convulsions and coma, bradycardia, respiratory depression. Symptoms of CNS stimulation are anxiety, agitation, hallucinations, and seizures. Symptoms of CNS depression include a decrease in body temperature, lethargy, drowsiness, and coma.
In addition, the following symptoms may develop: mydriasis, miosis, increased sweating, fever, pallor, cyanosis of the lips, disorders of the cardiovascular system (including cardiac arrest), respiratory failure (including respiratory failure, respiratory arrest), psychological disorders.

Treatment: In case of nasal overdose, immediately flush or clear the nose. Symptomatic treatment may be required.

Drug interactions
Some antidepressants (MAO inhibitors and tricyclic antidepressants) and vasoconstrictors, when administered simultaneously, can cause an increase in blood pressure.
Combination with tricyclic antidepressants may lead to the development of arrhythmia.
Concomitant use with antihypertensive agents (especially those that affect the sympathetic nervous system) may lead to various cardiovascular effects.

Terms of dispensing from pharmacies
The drug is approved for use as an over-the-counter drug.

Conditions and terms of storage
The drug should be stored out of the reach of children at a temperature not exceeding 25°C.